Humana Inc. (NYSE:HUM) Shares Sold by American International Group Inc.

American International Group Inc. lowered its position in shares of Humana Inc. (NYSE:HUM) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,836 shares of the insurance provider’s stock after selling 1,040 shares during the period. American International Group Inc.’s holdings in Humana were worth $17,780,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in Humana during the fourth quarter worth approximately $676,800,000. Sanders Capital LLC purchased a new position in shares of Humana in the 4th quarter valued at $489,300,000. Putnam Investments LLC raised its stake in Humana by 550.3% during the 4th quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock worth $400,808,000 after acquiring an additional 740,858 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Humana by 35.9% in the third quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after acquiring an additional 402,559 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Humana by 39.3% in the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after acquiring an additional 192,546 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.2 %

NYSE HUM traded up $0.83 during mid-day trading on Friday, hitting $358.93. The company’s stock had a trading volume of 867,077 shares, compared to its average volume of 1,316,634. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The stock’s fifty day simple moving average is $336.24 and its two-hundred day simple moving average is $358.94. The firm has a market capitalization of $43.25 billion, a P/E ratio of 22.34, a price-to-earnings-growth ratio of 2.11 and a beta of 0.53.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the business posted $9.38 EPS. The business’s quarterly revenue was up 10.7% on a year-over-year basis. Research analysts expect that Humana Inc. will post 16 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is presently 22.04%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HUM. Oppenheimer decreased their target price on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Barclays cut their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. UBS Group reduced their price target on shares of Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Argus downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Finally, Royal Bank of Canada reduced their target price on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Thirteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus target price of $423.63.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.